Tranzyme, Neokimia to merge

Functional biology company Tranzyme ( Research Triangle Park, N.C.) and medicinal chemistry play Neokimia (Sherbrooke, Quebec) will merge in a 50-50 share deal. The new company will be called Tranzyme and will develop therapeutics for diseases related to the "brain-gut axis." Tranzyme has one preclinical compound and another in lead optimization in undisclosed neurology indications. Neokimia has leads in gastrointestinal and metabolic indications, including irritable bowel syndrome (IBS) and post operative ileus. The combined company expects to have two compounds in clinical development in 2005. ...